Premium
Venlafaxine and antihypertensive drugs
Author(s) -
Lam Y. W. Francis
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30368
Subject(s) - venlafaxine , medicine , pharmacology , reuptake inhibitor , pharmacokinetics , reuptake , venlafaxine hydrochloride , drug , antidepressant , serotonin , receptor , hippocampus
Drug interactions with psychotropic agents can occur in patients with cardiovascular disease who are receiving treatment for depressive symptoms. Although the serotonin‐norepinephrine reuptake inhibitor venlafaxine has a favorable safety profile in general, its effect on the noradrenergic system could worsen hypertension. In addition, venlafaxine metabolism is dependent on multiple CYP enzymes, and its pharmacokinetic profile could be changed by concurrently administered antihypertensive agents.